Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Next Previous
Search
Trial Profile

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms CheckMate153
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 01 Nov 2024 Results assessing efficacy of immune checkpoint blockade nivolumab published in the Nature Medicine.
    • 19 Apr 2023 Results(n=58) assessing Changes in the genomic and neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab presented at the 114th Annual Meeting of the American Association for Cancer Research
    • 03 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top